Review



plau item no  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Proteintech plau item no
    Fig. 3. Overexpression of <t>PLAU</t> is related to PNI in patients with HNSCC. a Typical picture of Ki67, PLAU, <t>NGF,</t> <t>PGP9.5</t> in tissue microarrays staining of 68 patients with laryngeal and hypopharyngeal carcinomas. b-e Statistical analysis of Ki67, PLAU, NGF, PGP9.5 expression in PNI positive and negative patients. f-h Spearman correlation between PLAU, NGF and PGP9.5. ***P < 0.001, ****P < 0.0001.
    Plau Item No, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 44 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plau item no/product/Proteintech
    Average 94 stars, based on 44 article reviews
    plau item no - by Bioz Stars, 2026-03
    94/100 stars

    Images

    1) Product Images from "PLAU serves as a prognostic biomarker correlated with perineural invasion in HNSCC."

    Article Title: PLAU serves as a prognostic biomarker correlated with perineural invasion in HNSCC.

    Journal: Cancer genetics

    doi: 10.1016/j.cancergen.2025.04.008

    Fig. 3. Overexpression of PLAU is related to PNI in patients with HNSCC. a Typical picture of Ki67, PLAU, NGF, PGP9.5 in tissue microarrays staining of 68 patients with laryngeal and hypopharyngeal carcinomas. b-e Statistical analysis of Ki67, PLAU, NGF, PGP9.5 expression in PNI positive and negative patients. f-h Spearman correlation between PLAU, NGF and PGP9.5. ***P < 0.001, ****P < 0.0001.
    Figure Legend Snippet: Fig. 3. Overexpression of PLAU is related to PNI in patients with HNSCC. a Typical picture of Ki67, PLAU, NGF, PGP9.5 in tissue microarrays staining of 68 patients with laryngeal and hypopharyngeal carcinomas. b-e Statistical analysis of Ki67, PLAU, NGF, PGP9.5 expression in PNI positive and negative patients. f-h Spearman correlation between PLAU, NGF and PGP9.5. ***P < 0.001, ****P < 0.0001.

    Techniques Used: Over Expression, Staining, Expressing

    Fig. 4. PLAU is able to promote the capacity of proliferation and migration in HNSCC cells. a, b WB validation of the knockdown and overexpression efficiency of PLAU in FaDu and Tu686 cells. c, d The CCK8 assay measured the effect of PLAU inhibition or overexpression on cell proliferation. e-g Transwell assay was used to assess the effect of inhibiting or overexpressing PLAU on cell migration ability. h-j Addition of some inhibitors of PLAU and NGF respectively to detect changes in the ability of cell proliferation and migration by CCK8 and Transwell assays. **P < 0.01, ***P < 0.001.
    Figure Legend Snippet: Fig. 4. PLAU is able to promote the capacity of proliferation and migration in HNSCC cells. a, b WB validation of the knockdown and overexpression efficiency of PLAU in FaDu and Tu686 cells. c, d The CCK8 assay measured the effect of PLAU inhibition or overexpression on cell proliferation. e-g Transwell assay was used to assess the effect of inhibiting or overexpressing PLAU on cell migration ability. h-j Addition of some inhibitors of PLAU and NGF respectively to detect changes in the ability of cell proliferation and migration by CCK8 and Transwell assays. **P < 0.01, ***P < 0.001.

    Techniques Used: Migration, Biomarker Discovery, Knockdown, Over Expression, CCK-8 Assay, Inhibition, Transwell Assay

    Fig. 6. PLAU promotes tumor growth in vivo. a Schematic of mice subcutaneous tumorigenesis model. b-d FaDu cells were transplanted subcutaneously into nude mice and divided into NC, UKI-1 and Ro 08-2750 groups (UKI-1 and Ro 08-2750 inhibit PLAU and NGF, respectively). The corresponding drugs were injected intraperitoneally on days 1, 4, 7, 10, 13, 16 and 19, the tumors were removed on day 22 and the weight and volume of subcutaneous tumors were measured. e-g The same method was adopted for Tu686 cells as in b-d. h-l Representative immunohistochemical staining of Ki67, PLAU, NGF, PGP9.5 and statistical analysis of respective staining intensity scores. m Schematic overview of interaction between nerve cells and HNSCC cells. Briefly, HNSCC cells have the capability to secrete PLAU and NGF to nerve cells, facilitating the development of PNI and subsequently enhancing tumor advancement. On this basis, the inhibition of PLAU and NGF through UKI-1 and Ro 08-2750 has proven to be efficacious in impeding tumor progression. *P < 0.05, **P < 0.01, ***P < 0.001.
    Figure Legend Snippet: Fig. 6. PLAU promotes tumor growth in vivo. a Schematic of mice subcutaneous tumorigenesis model. b-d FaDu cells were transplanted subcutaneously into nude mice and divided into NC, UKI-1 and Ro 08-2750 groups (UKI-1 and Ro 08-2750 inhibit PLAU and NGF, respectively). The corresponding drugs were injected intraperitoneally on days 1, 4, 7, 10, 13, 16 and 19, the tumors were removed on day 22 and the weight and volume of subcutaneous tumors were measured. e-g The same method was adopted for Tu686 cells as in b-d. h-l Representative immunohistochemical staining of Ki67, PLAU, NGF, PGP9.5 and statistical analysis of respective staining intensity scores. m Schematic overview of interaction between nerve cells and HNSCC cells. Briefly, HNSCC cells have the capability to secrete PLAU and NGF to nerve cells, facilitating the development of PNI and subsequently enhancing tumor advancement. On this basis, the inhibition of PLAU and NGF through UKI-1 and Ro 08-2750 has proven to be efficacious in impeding tumor progression. *P < 0.05, **P < 0.01, ***P < 0.001.

    Techniques Used: In Vivo, Injection, Immunohistochemical staining, Staining, Inhibition



    Similar Products

    plau item no  (Proteintech)
    94
    Proteintech plau item no
    Fig. 3. Overexpression of <t>PLAU</t> is related to PNI in patients with HNSCC. a Typical picture of Ki67, PLAU, <t>NGF,</t> <t>PGP9.5</t> in tissue microarrays staining of 68 patients with laryngeal and hypopharyngeal carcinomas. b-e Statistical analysis of Ki67, PLAU, NGF, PGP9.5 expression in PNI positive and negative patients. f-h Spearman correlation between PLAU, NGF and PGP9.5. ***P < 0.001, ****P < 0.0001.
    Plau Item No, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plau item no/product/Proteintech
    Average 94 stars, based on 1 article reviews
    plau item no - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 3. Overexpression of PLAU is related to PNI in patients with HNSCC. a Typical picture of Ki67, PLAU, NGF, PGP9.5 in tissue microarrays staining of 68 patients with laryngeal and hypopharyngeal carcinomas. b-e Statistical analysis of Ki67, PLAU, NGF, PGP9.5 expression in PNI positive and negative patients. f-h Spearman correlation between PLAU, NGF and PGP9.5. ***P < 0.001, ****P < 0.0001.

    Journal: Cancer genetics

    Article Title: PLAU serves as a prognostic biomarker correlated with perineural invasion in HNSCC.

    doi: 10.1016/j.cancergen.2025.04.008

    Figure Lengend Snippet: Fig. 3. Overexpression of PLAU is related to PNI in patients with HNSCC. a Typical picture of Ki67, PLAU, NGF, PGP9.5 in tissue microarrays staining of 68 patients with laryngeal and hypopharyngeal carcinomas. b-e Statistical analysis of Ki67, PLAU, NGF, PGP9.5 expression in PNI positive and negative patients. f-h Spearman correlation between PLAU, NGF and PGP9.5. ***P < 0.001, ****P < 0.0001.

    Article Snippet: After a series of tissue dewaxing, hydration and antigen repair, a drop of primary antibody was added (the concentration of antibody was adjusted slightly according to the actual situation, PGP9.5 Item No. Abclonal A19101 1:100, PLAU Item No. Proteintech 17968-1-AP 1:100, NGF Item No. Abcam ab52918 1:200, KI67 Item No. Proteintech 27309- 1-AP 1:1000).

    Techniques: Over Expression, Staining, Expressing

    Fig. 4. PLAU is able to promote the capacity of proliferation and migration in HNSCC cells. a, b WB validation of the knockdown and overexpression efficiency of PLAU in FaDu and Tu686 cells. c, d The CCK8 assay measured the effect of PLAU inhibition or overexpression on cell proliferation. e-g Transwell assay was used to assess the effect of inhibiting or overexpressing PLAU on cell migration ability. h-j Addition of some inhibitors of PLAU and NGF respectively to detect changes in the ability of cell proliferation and migration by CCK8 and Transwell assays. **P < 0.01, ***P < 0.001.

    Journal: Cancer genetics

    Article Title: PLAU serves as a prognostic biomarker correlated with perineural invasion in HNSCC.

    doi: 10.1016/j.cancergen.2025.04.008

    Figure Lengend Snippet: Fig. 4. PLAU is able to promote the capacity of proliferation and migration in HNSCC cells. a, b WB validation of the knockdown and overexpression efficiency of PLAU in FaDu and Tu686 cells. c, d The CCK8 assay measured the effect of PLAU inhibition or overexpression on cell proliferation. e-g Transwell assay was used to assess the effect of inhibiting or overexpressing PLAU on cell migration ability. h-j Addition of some inhibitors of PLAU and NGF respectively to detect changes in the ability of cell proliferation and migration by CCK8 and Transwell assays. **P < 0.01, ***P < 0.001.

    Article Snippet: After a series of tissue dewaxing, hydration and antigen repair, a drop of primary antibody was added (the concentration of antibody was adjusted slightly according to the actual situation, PGP9.5 Item No. Abclonal A19101 1:100, PLAU Item No. Proteintech 17968-1-AP 1:100, NGF Item No. Abcam ab52918 1:200, KI67 Item No. Proteintech 27309- 1-AP 1:1000).

    Techniques: Migration, Biomarker Discovery, Knockdown, Over Expression, CCK-8 Assay, Inhibition, Transwell Assay

    Fig. 6. PLAU promotes tumor growth in vivo. a Schematic of mice subcutaneous tumorigenesis model. b-d FaDu cells were transplanted subcutaneously into nude mice and divided into NC, UKI-1 and Ro 08-2750 groups (UKI-1 and Ro 08-2750 inhibit PLAU and NGF, respectively). The corresponding drugs were injected intraperitoneally on days 1, 4, 7, 10, 13, 16 and 19, the tumors were removed on day 22 and the weight and volume of subcutaneous tumors were measured. e-g The same method was adopted for Tu686 cells as in b-d. h-l Representative immunohistochemical staining of Ki67, PLAU, NGF, PGP9.5 and statistical analysis of respective staining intensity scores. m Schematic overview of interaction between nerve cells and HNSCC cells. Briefly, HNSCC cells have the capability to secrete PLAU and NGF to nerve cells, facilitating the development of PNI and subsequently enhancing tumor advancement. On this basis, the inhibition of PLAU and NGF through UKI-1 and Ro 08-2750 has proven to be efficacious in impeding tumor progression. *P < 0.05, **P < 0.01, ***P < 0.001.

    Journal: Cancer genetics

    Article Title: PLAU serves as a prognostic biomarker correlated with perineural invasion in HNSCC.

    doi: 10.1016/j.cancergen.2025.04.008

    Figure Lengend Snippet: Fig. 6. PLAU promotes tumor growth in vivo. a Schematic of mice subcutaneous tumorigenesis model. b-d FaDu cells were transplanted subcutaneously into nude mice and divided into NC, UKI-1 and Ro 08-2750 groups (UKI-1 and Ro 08-2750 inhibit PLAU and NGF, respectively). The corresponding drugs were injected intraperitoneally on days 1, 4, 7, 10, 13, 16 and 19, the tumors were removed on day 22 and the weight and volume of subcutaneous tumors were measured. e-g The same method was adopted for Tu686 cells as in b-d. h-l Representative immunohistochemical staining of Ki67, PLAU, NGF, PGP9.5 and statistical analysis of respective staining intensity scores. m Schematic overview of interaction between nerve cells and HNSCC cells. Briefly, HNSCC cells have the capability to secrete PLAU and NGF to nerve cells, facilitating the development of PNI and subsequently enhancing tumor advancement. On this basis, the inhibition of PLAU and NGF through UKI-1 and Ro 08-2750 has proven to be efficacious in impeding tumor progression. *P < 0.05, **P < 0.01, ***P < 0.001.

    Article Snippet: After a series of tissue dewaxing, hydration and antigen repair, a drop of primary antibody was added (the concentration of antibody was adjusted slightly according to the actual situation, PGP9.5 Item No. Abclonal A19101 1:100, PLAU Item No. Proteintech 17968-1-AP 1:100, NGF Item No. Abcam ab52918 1:200, KI67 Item No. Proteintech 27309- 1-AP 1:1000).

    Techniques: In Vivo, Injection, Immunohistochemical staining, Staining, Inhibition